Figure 4

Mo-MDSC levels tend to normalize to healthy controls levels during systemic treatment. Flow cytometric analyzes of PBMCs from healthy controls (HC) and breast cancer patients before (baseline; BL), at 1 month, at 3 months or 6 months of treatment. (a–c, left panels) Percentages of CD14⁺HLA-DR^low/− Mo-MDSCs of PBMCs (a), Mo-MDSCs of CD14⁺ cells (b) or total CD14⁺ monocytes (c), depicted over time for individual patients treated with either chemotherapy (ChT, black symbols, n = 2) or endocrine therapy (ET, white symbols, n = 3). Dashed line represents median HC. Exact p-values, by Wilcoxon signed-rank test, are indicated. (a–c, right panels) Fold change as compared to BL of Mo-MDSCs of PBMCs (a), Mo-MDSCs of CD14⁺ cells (b) or all CD14⁺ monocytes (c) upon treatment with chemotherapy (ChT, black symbols n = 2) or endocrine therapy (ET, white symbols n = 3). Dashed line represents BL levels (set to 1). Exact p-values, by Wilcoxon signed-rank test are indicated.